Skip to content
zameds

Eculizumab (Soliris)

Eculizumab

Astrazeneca Pharmaceuticals (Pty) Ltd

Registration

Applicant
Astrazeneca Pharmaceuticals (Pty) Ltd
Certificate holder
Astrazeneca Pharmaceuticals (Pty) Ltd
Registrations
1

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Soliris

EACH VIAL CONTAINS: ECULIZUMAB 300,0 mg

300 mgConcentrate for solution for infusion61080761/30.1/0807Approved 17 March 2026RegisteredNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

No structure available

This product's active ingredient could not be matched to a single known compound.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles